Osimertinib in advanced non-small cell lung cancer (NSCLC) harboring different EGFR uncommon variants: real-world data from the Italian biomarker ATLAS database
Background Uncommon EGFR mutations (ucEGFR mut) account for 10%-15% of epidermal growth factor receptor (EGFR) oncogenic alterations in non-small cell lung cancer (NSCLC) and display heterogeneous sensitivity to EGFR tyrosine kinase inhibitors. Materials and methods Clinical, pathological, and molecular data from patie...